Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses

Lung metastasis is a leading cause of cancer-related deaths. Here, we show that intranasal delivery of our engineered CpG-coated tumor antigen (Tag)-encapsulated nanoparticles (NPs)—nasal nano-vaccine—significantly reduced lung colonization by intravenous challenge of an extra-pulmonary tumor. Prote...

Full description

Bibliographic Details
Published in:Pharmaceutics
Main Authors: Michael Donkor, Jamie Choe, Danielle Marie Reid, Byron Quinn, Mark Pulse, Amalendu Ranjan, Pankaj Chaudhary, Harlan P. Jones
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Subjects:
breast cancer
lung metastasis
vaccination
immune response
nanoparticles
Online Access:https://www.mdpi.com/1999-4923/15/2/445
Description
Summary:Lung metastasis is a leading cause of cancer-related deaths. Here, we show that intranasal delivery of our engineered CpG-coated tumor antigen (Tag)-encapsulated nanoparticles (NPs)—nasal nano-vaccine—significantly reduced lung colonization by intravenous challenge of an extra-pulmonary tumor. Protection against tumor-cell lung colonization was linked to the induction of localized mucosal-associated effector and resident memory T cells as well as increased bronchiolar alveolar lavage-fluid IgA and serum IgG antibody responses. The nasal nano-vaccine-induced T-cell-mediated antitumor mucosal immune response was shown to increase tumor-specific production of IFN-γ and granzyme B by lung-derived CD8<sup>+</sup> T cells. These findings demonstrate that our engineered nasal nano-vaccine has the potential to be used as a prophylactic approach prior to the seeding of tumors in the lungs, and thereby prevent overt lung metastases from existing extra pulmonary tumors.
ISSN:1999-4923

Similar Items